» Articles » PMID: 31417914

Serum Vitamin D Metabolites and CXCL10 Concentrations Associate With Survival in Dogs With Immune Mediated Disease

Overview
Journal Front Vet Sci
Date 2019 Aug 17
PMID 31417914
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Low vitamin D increases the risk of immune-mediated disease (IMD) in human beings and rodent models. Vitamin D metabolites, particularly 1,25(OH)2D3, modulate gene expression of immune cells and may attenuate immune pathways that drive IMD. Our primary hypothesis was that serum 25(OH)D3 and 1,25(OH)2D3, are reduced in patients with IMD and associate with poorer outcomes. We secondarily hypothesized serum 24,25(OH)2D3 would not be associated with disease or outcome. We also measured serum CXCL10 concentrations to determine if an increase occurs in dogs with IMD and in association with poorer survival. We enrolled dogs diagnosed with IMD ( = 29) and healthy control dogs ( = 9) in the study with informed client consent. Serum was collected and stored at -80°C until analyses. Serum vitamin D metabolites were measured by LC-MS/MS by an accredited laboratory. A commercially available canine-specific ELISA kit measured serum CXCL10. Serum 25(OH)D3 and 1,25(OH)2D3 were significantly reduced in dogs ( = 25) with IMD. Serum CXCL10 concentrations undetectable in all controls, and were 30 times higher overall in IMD dogs ( = 25; = 0.004). CXL10 was, however, undetectable in 40% of dogs with IMD. Of the 60% of IMD dogs with increased CXCL10 concentrations, 5/25 had concentrations at the upper limit of quantification. The survival of those five dogs was significantly ( = 0.049) shorter (72 days) than all other dogs with IMD with measured CXCL10 concentrations. The median survival time (MST) for dogs with 25(OH)D3 concentrations ≤ the median was 106 days, while dogs with concentrations of 25(OH)D3 > the median did not achieve an MST. Serum 25(OH)D3 and 1,25(OH)2D3, but not 24,25(OH)2D3 levels are reduced dogs with IMD. Vitamin D metabolites and CXCL10 may be useful prognostic markers and may be targets for adjunct therapy in canine IMD. These data support the future investigation of vitamin D analogs in the treatment of canine IMD.

Citing Articles

A Novel UHPLC-MS/MS Method for the Measurement of 25-Hydroxyvitamin D3 in Canine Serum and Its Application to Healthy Dogs.

Bardhi A, Vecchiato C, Sabetti M, Tardo A, Vasylyeva K, Biagi G Animals (Basel). 2024; 14(1).

PMID: 38200793 PMC: 10778062. DOI: 10.3390/ani14010062.


The effects of age, sex, breed, diet, reproductive status and housing condition on the amounts of 25(OH) vitamin D in the serum of healthy dogs: Reference values.

Alizadeh K, Ahmadi S, Sarchahi A, Mohri M Vet Med Sci. 2022; 8(6):2360-2366.

PMID: 36137283 PMC: 9677387. DOI: 10.1002/vms3.943.


Rapid improvement in vitamin D status with dietary 25-hydroxycholecalciferol in vitamin D insufficient dogs.

Kurzbard R, Backus R, Yu S J Nutr Sci. 2021; 10:e12.

PMID: 33889395 PMC: 8057436. DOI: 10.1017/jns.2021.4.


Serum 25-hydroxyvitamin D concentration and infectious respiratory disease complex in shelter dogs.

Jaffey J, Lappin M, Ringold R, Kreisler R, Bradley-Siemens N, Hawley J J Vet Intern Med. 2020; 35(1):472-479.

PMID: 33319408 PMC: 7848350. DOI: 10.1111/jvim.16008.


Vitamin D Binding Protein (VDBP) and Its Gene Polymorphisms-The Risk of Malignant Tumors and Other Diseases.

Rozmus D, Ciesielska A, Plominski J, Grzybowski R, Fiedorowicz E, Kordulewska N Int J Mol Sci. 2020; 21(21).

PMID: 33105665 PMC: 7659952. DOI: 10.3390/ijms21217822.


References
1.
Overbergh L, Decallonne B, Valckx D, Verstuyf A, Depovere J, Laureys J . Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol. 2000; 120(1):139-46. PMC: 1905630. DOI: 10.1046/j.1365-2249.2000.01204.x. View

2.
van Etten E, Branisteanu D, Verstuyf A, Waer M, Bouillon R, Mathieu C . Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. Transplantation. 2000; 69(9):1932-42. DOI: 10.1097/00007890-200005150-00032. View

3.
Gerber B, Hassig M, Reusch C . Serum concentrations of 1,25-dihydroxycholecalciferol and 25-hydroxycholecalciferol in clinically normal dogs and dogs with acute and chronic renal failure. Am J Vet Res. 2003; 64(9):1161-6. DOI: 10.2460/ajvr.2003.64.1161. View

4.
Campbell J, Gangur V, Simons F, HayGlass K . Allergic humans are hyporesponsive to a CXCR3 ligand-mediated Th1 immunity-promoting loop. FASEB J. 2003; 18(2):329-31. DOI: 10.1096/fj.02-0908fje. View

5.
Munger K, Zhang S, OReilly E, Hernan M, Olek M, Willett W . Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004; 62(1):60-5. DOI: 10.1212/01.wnl.0000101723.79681.38. View